Praluent vs Lisinopril: Switching Between Them

Why Comparing Alirocumab to Lisinopril Is Clinically Unusual

Alirocumab and lisinopril sit in entirely different parts of the cardiovascular pharmacology tree. One is a biologic that attacks LDL cholesterol at the PCSK9 pathway. The other is a small-molecule ACE inhibitor that reduces blood pressure and afterload. A patient rarely needs to choose one over the other, because the conditions that prompt their use are different enough that most patients with established coronary disease are on both.

No randomized head-to-head trial has compared alirocumab to lisinopril directly. The question most often arises when a prescriber or patient wants to understand whether one drug can substitute for the other after a side effect or cost problem. The short answer is no. The longer answer requires understanding what each drug actually does in the body.

Alirocumab: What It Does and What It Does Not Do

Alirocumab binds PCSK9, a protein that degrades LDL receptors on hepatocytes 1. By blocking PCSK9, the drug increases LDL receptor recycling, which pulls more LDL-C out of the bloodstream. At the 150 mg every-2-weeks dose, alirocumab reduces LDL-C by approximately 54-62% from baseline on top of maximally tolerated statin therapy 2.

Alirocumab does not meaningfully lower blood pressure. It has no direct effect on the renin-angiotensin-aldosterone system (RAAS). A patient stopping lisinopril and starting alirocumab instead would lose all blood pressure control provided by the ACE inhibitor.

Lisinopril: What It Does and What It Does Not Do

Lisinopril blocks angiotensin-converting enzyme, which reduces the conversion of angiotensin I to angiotensin II 3. The result is arterial vasodilation, reduced sodium retention, and lower blood pressure. In the ALLHAT trial (N=33,357), lisinopril produced blood pressure control equivalent to chlorthalidone for combined fatal coronary heart disease and nonfatal myocardial infarction, though stroke rates were higher in the lisinopril arm 4.

Lisinopril does not lower LDL-C. A patient stopping alirocumab and switching to lisinopril would retain whatever blood pressure benefit they had but would lose all LDL-lowering beyond what their statin provides.

The ODYSSEY OUTCOMES Trial: What Alirocumab Actually Proved

ODYSSEY OUTCOMES enrolled 18,924 patients with a recent acute coronary syndrome who were already on high-intensity or maximally tolerated statin therapy 5. The trial randomized patients to alirocumab 75 mg every 2 weeks (titrated to 150 mg if needed) or placebo.

Primary Outcome Results

At a median follow-up of 2.8 years, alirocumab reduced the primary composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15% relative risk reduction (hazard ratio 0.85, 95% CI 0.78-0.93, P<0.001) 6. The absolute risk reduction was 1.6 percentage points (11.1% vs. 9.5%). Number needed to treat was 63 over 2.8 years.

Mortality Signal

A pre-specified secondary analysis showed all-cause mortality was 3.5% in the alirocumab group versus 4.1% in the placebo group (HR 0.85, 95% CI 0.73-0.98) 7. This was the first PCSK9 inhibitor trial to show a mortality signal, though it was a secondary endpoint and the confidence interval was wide.

Who Benefits Most

The mortality benefit was concentrated in patients with baseline LDL-C at or above 100 mg/dL. Patients with baseline LDL-C below 80 mg/dL showed attenuated benefit, which has informed current prescribing guidelines from the American College of Cardiology recommending a threshold-based approach before adding a PCSK9 inhibitor to statin therapy 8.

The ALLHAT Trial: What Lisinopril Actually Proved

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) is one of the largest antihypertensive trials ever conducted, with 33,357 high-risk hypertensive patients randomized to chlorthalidone, amlodipine, or lisinopril 9.

Primary Outcome Results

For the primary outcome of fatal coronary heart disease or nonfatal MI, lisinopril was equivalent to chlorthalidone (relative risk 0.99, 95% CI 0.91-1.08) 10. Lisinopril was therefore confirmed as an effective first-line antihypertensive for patients at high cardiovascular risk.

The Stroke Finding

Stroke incidence was 15% higher in the lisinopril arm versus chlorthalidone (RR 1.15, 95% CI 1.02-1.30) 11. This difference was partly attributed to less effective blood pressure lowering with lisinopril in Black patients, a finding that reinforced current JNC and ACC/AHA guideline recommendations to consider thiazide diuretics or calcium channel blockers as preferred first-line agents in Black patients with hypertension 12.

Where Lisinopril Excels

The guideline-supported strength of lisinopril is in patients with heart failure with reduced ejection fraction (HFrEF), diabetic nephropathy, and post-MI left ventricular dysfunction. In these populations, RAAS blockade reduces mortality independently of blood pressure effects 13.

Switching Between Alirocumab and Lisinopril: The Clinical Scenarios

No clinical guideline recommends switching from alirocumab to lisinopril or vice versa as a direct therapeutic substitution. They treat separate pathologies. However, three distinct scenarios prompt the question.

Scenario 1: Stopping Alirocumab Due to Cost or Access

Alirocumab carries a list price of approximately $550 per month. When a patient loses insurance coverage or prior authorization, a prescriber cannot replace it with lisinopril. The appropriate substitution path is to optimize statin dose first, then consider ezetimibe 10 mg daily (which adds a further 18-20% LDL-C reduction) 14, then reassess PCSK9 inhibitor eligibility. Sanofi's patient assistance program provides alirocumab at no cost to eligible uninsured patients, which is worth exploring before any switch.

Scenario 2: Stopping Lisinopril Due to Cough or Angioedema

ACE inhibitor-induced cough occurs in 5-20% of patients, with higher rates in Asian populations 15. Angioedema is rarer but potentially life-threatening. Neither symptom is resolved by adding or switching to alirocumab, because alirocumab has no RAAS activity. The appropriate substitution for lisinopril in this setting is an angiotensin receptor blocker (ARB) such as losartan or valsartan, which provides equivalent RAAS blockade without bradykinin accumulation 16.

Scenario 3: A Patient on Both Drugs Who Needs to Stop One

Patients with post-ACS hyperlipidemia and hypertension may be on both alirocumab and lisinopril simultaneously. If a clinical decision is made to reduce the medication burden, the choice of which to stop depends entirely on which condition is being managed:

• If LDL-C is at goal on statin monotherapy (below 70 mg/dL per ACC/AHA 2018 guidelines) and the PCSK9 inhibitor was added for further reduction, that is the candidate for discontinuation.
• If blood pressure is controlled without the ACE inhibitor because the patient's underlying hypertension resolved after weight loss or other intervention, lisinopril may be tapered.
• Neither drug should be stopped abruptly without reassessing the condition it was treating.

Mechanism Comparison: PCSK9 Inhibition vs. ACE Inhibition

Understanding the mechanistic difference helps explain why these drugs are not interchangeable.

PCSK9 Inhibition Pathway

PCSK9 is a serine protease secreted by the liver that binds LDL receptors and directs them for lysosomal degradation 17. Alirocumab is a fully human IgG1 monoclonal antibody. It binds PCSK9 in the circulation before PCSK9 can contact the LDL receptor. The result is more LDL receptors on the hepatocyte surface, faster LDL clearance, and lower plasma LDL-C. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical ATHEROSCLEROTIC cardiovascular disease requiring additional LDL-C lowering 18.

ACE Inhibition Pathway

Lisinopril competitively inhibits angiotensin-converting enzyme, blocking the conversion of angiotensin I to the vasoconstrictor angiotensin II 19. This reduces systemic vascular resistance and aldosterone secretion, lowering both systolic and diastolic blood pressure. In heart failure, reduced afterload and preload improve cardiac output. ACE inhibitors also accumulate bradykinin, which contributes both to the antihypertensive effect and to the characteristic dry cough side effect 20.

Side-Effect Profiles: Where They Differ

Alirocumab Side Effects

The most common adverse events with alirocumab in ODYSSEY OUTCOMES were injection-site reactions (3.8% vs. 2.1% placebo) and influenza-like symptoms 21. Neurocognitive events were monitored specifically given theoretical concerns about very low LDL-C; no statistically significant difference was observed versus placebo (1.2% vs. 1.1%) 22. New-onset diabetes rates were also similar between groups.

Lisinopril Side Effects

Dry cough is the most common adverse effect of lisinopril, affecting 5-20% of users 23. Angioedema occurs in 0.1-0.7% of patients and is a contraindication to continued ACE inhibitor use 24. Hyperkalemia and acute kidney injury are risks in patients with chronic kidney disease or those taking potassium-sparing diuretics. First-dose hypotension can occur, especially in volume-depleted patients.

Guideline Recommendations: What ACC/AHA and ESC Say

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitors as third-line agents after high-intensity statin therapy and ezetimibe in very high-risk patients with ASCVD 25. The guideline states: "For very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable."

For hypertension management, the 2017 ACC/AHA Guideline on High Blood Pressure places ACE inhibitors including lisinopril as first-line agents for patients with hypertension and heart failure, post-MI status, or chronic kidney disease 26. The guideline notes that ACE inhibitors are not preferred as monotherapy in Black patients without these comorbidities.

These two drug classes occupy separate tiers in separate guidelines. A prescriber would never consult the cholesterol guideline to decide about lisinopril, nor the hypertension guideline to decide about alirocumab.

Cost and Access Considerations

Lisinopril is available as a generic and costs approximately $4-10 per month at most major pharmacies. Alirocumab has no generic equivalent and carries a list price near $550 per month. Prior authorization requirements from most U.S. Insurers require documented statin intolerance or inadequate LDL-C response to maximally tolerated statin plus ezetimibe before alirocumab is covered 27.

The cost gap is not a reason to switch between these drugs. It is, however, a reason to carefully confirm that each drug is serving a purpose that no cheaper alternative can fill before maintaining both on a patient's medication list.

Practical Decision Guide: Which Drug for Which Patient

Use Alirocumab When

• LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe in a patient with clinical ASCVD or HeFH.
• The patient has documented statin intolerance and cannot take high-intensity statins.
• Post-ACS risk is high and baseline LDL-C was at or above 100 mg/dL.

Use Lisinopril When

• Hypertension requires treatment, especially with comorbid heart failure, post-MI LV dysfunction, or diabetic nephropathy.
• A patient with HFrEF needs RAAS blockade for mortality reduction independent of blood pressure.
• Blood pressure is uncontrolled on lifestyle measures alone.

Use Both When

• A post-ACS patient has both LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe and hypertension or HFrEF requiring RAAS blockade.
• The combination is common in high-risk cardiovascular patients and is supported by the independent trial evidence from ODYSSEY OUTCOMES and ALLHAT respectively.

Stopping Alirocumab: What Happens to LDL-C

When alirocumab is discontinued, LDL-C returns to pre-treatment levels within approximately 8-12 weeks, matching the half-life of the antibody 28. There is no rebound above baseline. The underlying PCSK9 pathway simply resumes normal activity. Patients who stop alirocumab for any reason should have LDL-C rechecked at 12 weeks to confirm return to baseline and reassess the need for alternative intensification of lipid-lowering therapy.

Stopping Lisinopril: Blood Pressure Rebound Risk

Abrupt discontinuation of lisinopril does not cause the same rebound hypertension seen with beta-blockers or clonidine. Blood pressure typically returns toward pre-treatment levels over days to weeks, depending on the degree of RAAS dependence. Patients stopping lisinopril should have blood pressure monitored within 1-2 weeks. Those with heart failure or post-MI LV dysfunction require careful clinical reassessment before discontinuation, given the mortality benefit of RAAS blockade in those populations 29.